Group items tagged

The cost of liver cirrhosis transplant in India is just a fraction of what it is in the US, UK, and other developed nations.

The British Generic Manufacturers Association (BGMA) has elected Matthew Salzmann, UK Country Manager at Viatris, as its new Vice-Chair with immediate effect. He will replace the current chair of the BGMA, Diane DiGangi-Trench, who is the UK country head for Sandoz. Salzman, who is originally from Australia, has served approximately 1 billion patients worldwide last year as the UK Country Manager at Viatris, a global pharmaceutical company operating in 165 countries. In his role as BGMA Vice-Chair, Salzmann would focus on working in partnership with key stakeholders - the NHS, healthcare professionals, policy makers, clinical societies, patient associations, academia - to ensure access to affordable and sustainable medicines for patients and the NHS.

The Department of Health and Social Care (DHSC) today (19 October) issued its official response to an evaluation conducted by an independent expert panel from the Health and Social Care Committee (HSCC) regarding government commitments in the pharmacy sector. The joint agreement between DHSC, NHSE, and CPE (Community Pharmacy England) under a five-year plan commitment to review the funding model, however, the current status is "continue to monitor and discuss progress". The government has claimed that the panel's rating has "not been met" and still "requires improvement". However, the funding "remains subject to affordability and consultation with the sector on the activity that can be delivered within that funding envelope".

Recently launched generic version of Apixaban by Teva UK is said to bring savings to the NHS drug bill while making sure patients get the medicine they need. The generic apixaban is available for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Previously there was only a 'branded' product available, but Castleford-based Teva UK succeeded in invalidating the apixaban patent and SPC (supplementary protection certificate) in the UK High Court and so is now able to launch its own 'generic' version - which will bring savings for the NHS while making sure patients get the medicine they need. "We've always said that we stand up for the patient", said Kim Innes, General Manager of Teva UK and Ireland. "The launch of generic apixaban emphasises Teva's commitment to doing the right thing by putting patients at the heart of everything we do by giving them and the NHS access to affordable treatments." Apixaban is an anticoagulant which directly inhibits factor X (factor Xa), inhibiting thrombin formation and the development of thrombi (blood clots). For at-risk patients, such as those with, or at risk for DVT, or NVAF, the risk of stroke related to blood clots forming in the body and traveling to the brain is a serious concern. Each year, DVT affects around 1 person in every 1,000 in the UK and if left untreated, about 1 in 10 people with a DVT will develop a PE.

Thirty-five generic drug manufacturers will make a more affordable version of Pfizer's anti-Covid pill for the world's poorer nations, in licensing deals announced Thursday (17) by a UN-backed organisation. The global Medicines Patent Pool (MPP) signed agreements with three dozen manufacturers to produce the oral Covid-19 treatment nirmatrelvir for supply in 95 low- and middle-income countries. US pharmaceutical giant Pfizer signed a licence agreement with the MPP in November. The MPP, in turn, issued sub-licences to the generic drugs makers. The deals announced Thursday will "help ensure access to our oral Covid-19 treatment for patients in need around the world", said Pfizer chairman Albert Bourla.

Are you looking to start a career in the medical field but don't know where to begin? There are many different paths to choose from when it comes to entering the medical profession. It can be daunting trying to figure out which one is right for you. But with some research, planning, and dedication, you can find your way into this rewarding and fulfilling industry. Here are 8 tips that will help get you started on your journey toward becoming a successful healthcare professional. 1. ONLINE PROGRAMS If you have already decided on a career path and need to obtain additional qualifications or knowledge, there are many online programs available for medical professionals. These courses provide students with the opportunity to learn from home and gain experience in their chosen field without sacrificing the quality of education. You can find an online medical assistant programs, medical biller and coding programs, lab technician training, and more. It's important to research each program and make sure it's accredited before enrolling. While online programs may not offer the same hands-on experience as a traditional school, they can be an affordable and convenient way to get your foot in the door. 2. VOLUNTEERING OR WORKING IN A CLINICAL SETTING Volunteering or working part-time in a clinical setting is an excellent way to gain experience and decide if the medicine is the right profession for you. Even volunteer work can provide invaluable insight into how the medical field works, allowing you to network with professionals, observe procedures and treatment methods, and develop skills from patient interaction. Additionally, any volunteer work or job experience related to healthcare that appears on your resume establishes you as a serious candidate for a career in medicine. While you are likely to find many volunteer opportunities, be sure to do your research and only take positions in reputable organizations.

Low cost kidney transplant in India is much low as compared to international hospitals so Indian hospitals attract most of the international patients.

Amid media speculations that a large pharmacy multiple was putting all its stores at risk of closure, PSNC supremo Janet Morrison said the sector was in crisis and in danger of a significant collapse. Addressing delegates via a video link at Sigma Pharmaceutical's 13th Annual Community Pharmacy Conference held last week (March 4 -9) in Punta Cana, Dominican Republic, she said while "a lot of consolidation or sales" would continue, a lot of the smaller, independently-owned community pharmacies - which had to work harder and harder to make ends meet - were just "hanging on in there". "But I don't know how much longer people can go on," she said, adding that the risk of actual closure was rendering the remaining pharmacies so fragile that "they may not be able to pick up the slack of many thousands of patients" who would need repeat prescriptions. "The disruption is frightful and awful. We have got 53 per cent of the population on repeat prescriptions, so that matters." Her comment on the opening day of the conference was a sober reminder that the sector - which relies heavily on income from prescriptions - couldn't afford to "carry on with the current format of a contract and the current amount of money" it was paid to deliver numerous tasks which have been heaped on it to share the burden of a crippling NHS.

The new 'How to Involve and Engage Patients on Digital Health Tech Innovation' learning module has been created specifically to support the development and delivery of patient-centric technologies, at a time of critical digital transformation in the NHS. The foundation level module will be freely available at www.orcha-digitalhealthacademy.com and on the Health Education England NHS Learning Hub (learninghub.nhs.uk). No training previously exists on conducting effective patient and public involvement and engagement (PPIE), leading to wasted resource on unsuitable technologies at a time when the healthcare system simply cannot afford it. The module aims to educate innovators who are creating new technology, and the clinicians who are prescribing these solutions. Crucially, the module also provides valuable support to the 500 NHS clinicians who are on the Clinical Entrepreneur Programme. The module is an introduction to the first evidence-based framework for PPIE, launched by the University of Plymouth, the AHSN Network (the national voice of the 15 academic health science networks in England) and Boehringer Ingelheim UK & Ireland. It helps to fast-track learning for the EnACT principles described in the framework, outlining how to involve patients in product innovation and critical issues such as data privacy, intellectual property, inclusivity, reimbursement, useability, and recruitment of patients.

Boots witnessed a 'record-breaking' performance for beauty driving retail sales with a growth of 16 per cent in the three months to 28 February 2023. The beauty category delivered a record January, and premium beauty saw its biggest ever sales week in December. Skincare reported three consecutive weeks of record sales in December driven by the 'expert skincare' category in which brands including No7, La Roche-Posay, CeraVe and Eucerin proved popular. Boots beauty transformation strategy continued with 19 new beauty halls opened in Q2 and the 170th store to receive a beauty makeover opening at Westfield White City post-period end. Boots now stocks over 500 big name and cult beauty brands and exclusively sells the UK's leading skincare brand, No7. The business reported its eighth consecutive quarter of market share growth with gains across all categories, led by beauty - the stand-out performer of the quarter. Footfall, basket size and the number of Advantage Card customers all increased, as more people chose to shop at Boots. The Christmas period was particularly strong with retail sales in the five weeks to 31 December up 17.4% and outperforming the market. Boots further expanded its value offering in the quarter, announcing its biggest ever savings as part of its continued focus on the affordability of life's essentials. This included the addition of 60 new products to the Boots Everyday label as well as the extension of its Price Advantage scheme, which has to date resulted in £30 million of customer savings and now includes discounts on over 800 products every month.

National pharmacy bodies have expressed their disappointment on the launch date for Tier 1 of the Pharmacy Contraception Service which has been announced by NHS England (NHSE) as '24th April 2023′. Pharmaceutical Services Negotiating Committee (PSNC) said that this start date for the service has not been agreed with PSNC and is in direct contradiction of our warning to Ministers that no new or expanded services can be rolled out in 2023/24 unless extra funding is put into community pharmacies. Responding to this announcement, PSNC Chief Executive Janet Morrison said: "This is despite our warning last month that without additional funding, the roll-out of Year 5 additional services and the Pharmacy Quality Scheme is neither feasible nor affordable. Community pharmacies are having to work harder and harder for less money and many are at breaking point. And just this week the results of our 2023 Pharmacy Pressures Survey have confirmed the worsening situation. Clearly our view is not because contractors don't see the benefit of the service. This is a much-anticipated service that could deliver real benefits to patients and community pharmacies are always eager to support public health initiatives. But capacity in the sector is now so stretched that more money is needed to safely resource additional work. We have repeated our concerns to the Department in recent days and reminded them of the potential for a properly funded community pharmacy sector to play a greater role in providing clinical solutions and relieving pressures elsewhere in primary care."

The bone marrow transplant cost India provides a combination of top-notch professionals and extensive hematological expertise.

The Association of Independent Multiple Pharmacies (AIMp) has changed its name to the Independent Pharmacies Association (IPA). AIMp, now IPA, stated that rebranding was prompted by the demand from independent community pharmacists for an association that properly represents their interests. The membership of the Independent Pharmacies Association will not be restricted to pharmacy owners with multiple branches, as was the case with AIMp, but will be open to all independents, it announced today (Tuesday). It believes that the switch will "provide a clearer identity and afford a strong voice to the thousands of independent pharmacies in England and Wales." Furthermore, the IPA noted that it will not primarily function as an insurance organisation with membership attached, but it will be "fighting for and representing its members across all fronts."

Community Pharmacy England (CPE) has cautioned that patients in the UK will continue to encounter difficulties in accessing medicines unless the government addresses supply problems and resolves the critical financial state of community pharmacies. CPE Chief Executive Janet Morrison and Mike Dent, Director of Pharmacy Funding, on Monday 19 February, gave evidence to the Health and Social Care Select Committee's Pharmacy Inquiry, highlighting the impact of ongoing medicines supply issues on pharmacies and patients. Morrison indicated that a combination of the ongoing "financial squeeze, operational pressures, and medicines supply and pricing issues" has left pharmacy businesses fighting for survival. "As the NHS continues to grapple with wider challenges, this is a battle that patients cannot afford for pharmacies to lose," she said. Morrison warned that if pharmacies continue to close, not only business owners and pharmacy teams will suffer, but patients and local communities will also face the consequences.

P3 Healthcare Solutions is been offering professional medical billing services for quite some time now. The process starts from the consultation session where providers are informed about every detail from coding, billing to the latest strategies for smoothly running the revenue cycle. We aim to empower physicians with transparent and accurate billing practices.

The Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI) have reached an agreement on the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The landmark deal will save the NHS £14 billion over 5 years in medicines costs, boost the nation's health, and support research investment. The new VPAG scheme, which will be a non-contractual voluntary agreement between DHSC and ABPI, will run for 5 years from 1 January 2024 until 31 December 2028. It will double the annual allowed growth of sales of branded medicines from two per cent per year in 2024 to four per cent per year by 2027.

The Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns over the impact that high medicine price rises are having on contractor. Recently, the Department of Health and Social Care (DHSC) has granted the final list of price concessions for December 2022. The latest additions bring the total number of concessionary prices granted for the month of December to 198, surpassing the previous record of 159 granted in September 2022. PSNC has heard from hundreds of community pharmacy contractors who are paying inflated prices for antibiotics used for the treatment of Strep A and who have rightly been concerned about the lack of certainty around the final reimbursement prices for these medicines. It added: "We welcomed the involvement of the Competition and Markets Authority (CMA) to look into the pricing of antibiotics. But the number of reports we are getting from contractors about medicines price rises are just not acceptable and this goes far beyond the antibiotic crisis."

The UK GDP Association has been established as a non-profit organisation, operating as a Community Interest Company (CIC), with a focus on providing a broader support network, particularly for small and medium business enterprises and pharmacy wholesalers. In addition to delivering commercially viable Good Distribution Practice (GDP) consultancy services for simple models with smaller budgets, the association aims to function as a networking platform for Responsible Persons in the UK. As members of the association, companies and individuals can gain multiple benefits that will add value to their business through access to knowledge, discounted training, consultancy services, audit and inspection support, as well as resources like document templates for risk assessments, CAPA, deviations, and more. Moreover, members can enjoy the benefit of a like-minded support network via a dedicated GDP community hub, providing a platform for discussions, seeking advice, and fostering new relationships. "Our mission is to ensure that patient safety, GDP compliance, and excellent quality is paramount in all organisations, regardless of budget," the company said.